Trials / Completed
CompletedNCT00504959
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2007-07-20
- Last updated
- 2016-03-04
Locations
36 sites across 10 countries: Australia, Belgium, Germany, Hungary, Israel, Netherlands, Portugal, Spain, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00504959. Inclusion in this directory is not an endorsement.